You just read:

Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients

News provided by

Eiger BioPharmaceuticals, Inc.

Jun 06, 2017, 08:00 ET